Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04893083 · ClinicalTrials.gov registry record
A Non-interventional Study for the Collection of Biospecimens From Patients With Parkinson's Disease
A clinical trial, sponsored by Neuron23.
- Terminated
- Registry status
- 65
- Enrollment target
NCT04893083: Clinical Trial study, sponsored by Neuron23.
NCT04893083 is a clinical trial that was terminated before completion, run by Neuron23. The registered enrollment target is 65 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04893083 was terminated before completion, sponsored by Neuron23.
- TERMINATED
- Registry status
- 65 participants
- Enrollment target
Study Summary
This study aims to collect, analyze and preserve biospecimens from patients with or without LRRK2-associated Parkinson's Disease for the purpose of discovering and developing new treatments and novel biomarkers.
Primary Outcome
Test for LRRK2 mutations in Parkinson disease patients; identifying patients with potential genetic modifiers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2021-06-28 |
| Est. Completion | 2023-09-22 |
Why NCT04893083 stopped before completion
NCT04893083 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 65 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT04893083 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04893083 about?
NCT04893083 is a clinical study titled "A Non-interventional Study for the Collection of Biospecimens From Patients With Parkinson's Disease". This study aims to collect, analyze and preserve biospecimens from patients with or without LRRK2-associated Parkinson's Disease for the purpose of discovering and developing new treatments and novel biomarkers.
What is the current status of trial NCT04893083?
This trial is currently terminated. The enrollment target is 65 participants. The study started on 2021-06-28. Estimated completion is 2023-09-22.
Who is sponsoring clinical trial NCT04893083?
This trial is sponsored by Neuron23, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI